When was Lysosomal Therapeutics founded?

Lysosomal Therapeutics was founded in 2011 and raised its 1st funding round 3 years after it was founded.

Where is Lysosomal Therapeutics located?

Lysosomal Therapeutics is headquartered in Cambridge, United States.

How many employees does Lysosomal Therapeutics have?

As of Dec 31, 2019, Lysosomal Therapeutics has 8 employees, reflecting a 60% year-over-year decline in headcount.

Is Lysosomal Therapeutics a funded company?

Lysosomal Therapeutics is a funded company, having raised a total of $58M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 12, 2014.

When was the latest funding round of Lysosomal Therapeutics?

Lysosomal Therapeutics' latest funding was a $***** Series A round on Nov 07, 2019, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $2.52B in funding in 2026 to date.

Where does Lysosomal Therapeutics rank among its competitors?

Lysosomal Therapeutics ranks 177th amongst 452 active competitors, of which 159 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Mission Therapeutics, which secured $13.3M in Oct, 2025.

Who are the top competitors of Lysosomal Therapeutics?

Lysosomal Therapeutics' top competitors include Denali Therapeutics, Fulcrum Therapeutics and Juvenescence. Among them, Mission Therapeutics secured the most recent funding round in October, 2025.

Lysosomal Therapeutics - 2026 Company Profile, Funding & Competitors

Lysosomal Therapeutics is a series A company based in Cambridge (United States), founded in 2011. It operates as a Small molecules to target Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies.. Lysosomal Therapeutics has raised $58M in funding from investors like Atlas Venture, Lilly Ventures and Hatteras Venture Partners. The company has 452 active competitors, including 159 funded and 82 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Juvenescence.

Company Details

Lysosomal Therapeutics (LTI) is leveraging the genetic link between Gaucher (GD) and Parkinson’s Disease (PD) and is developing compounds that enhance the lysosomal glucocerebrosidase enzyme activity as an entirely new and potentially breakthrough class of agents for GD and PD. LTI has identified allosteric glucocerebrosidase activators that cross the blood brain barrier, restore lysosomal function and diminish a-synuclein accumulation in iPS cells of human midbrain dopaminergic neurons.

Key Metrics

Founded Year

2011

Location

Cambridge, United States

Stage

Series A

Total Funding

$58M in 6 rounds

Latest Funding Round

Series A, Nov 07, 2019, $*****

Investors

Atlas Venture & 12 more

Ranked

177^th among 452 active competitors

Employee Count

8 as on Dec 31, 2019

Similar Companies

Denali Therapeutics & 562 more

View Lysosomal Therapeutics' full profile

Lysosomal Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Lysosomal Therapeutics, Inc. CIN: 45-4015802 , United States, Active		-	8 (As on Dec 31, 2019)	-

Lysosomal Therapeutics has raised a total funding of $58M over 6 rounds. Its first funding round was on May 12, 2014. Lysosomal Therapeutics has 10 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of Lysosomal Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 07, 2019	9178971	Series A	6686466	5804385	1605943	9606648
Jan 13, 2017	2414632	Series A	6514509	7960238	8906268	Henri Termeer & 1 more
Oct 05, 2016	1360416	Series A	9809022	8299717	1953319	2468628

Access funding benchmarks and valuations. Sign up today!

View details of Lysosomal Therapeutics's funding rounds and investors

Lysosomal Therapeutics' employee count trend

Lysosomal Therapeutics has 8 employees as of Dec 19. The total employee count is 60.0% lower than what it was in Dec 18. Here is Lysosomal Therapeutics's employee count trend over the years:

Employee count trend for Lysosomal Therapeutics

Uncover Lysosomal Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lysosomal Therapeutics include Denali Therapeutics, Fulcrum Therapeutics and Juvenescence. Here is the list of Top 10 competitors of Lysosomal Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Baillie Gifford, Bezos Expeditions & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Ipgl, Foresite Capital & 9 others	68/100
4th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Blackstone, Redmile Group & 16 others	67/100
5th	Axsome Therapeutics 2012, New York City (United States), Public	Developer of therapeutic solutions for the management of CNS disorders	$8.7M	Collage Venture Partners, SVB Securities	66/100
6th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Orbimed, ATW Partners & 5 others	65/100
8th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$115M	RA Capital Management, SV Health Investors ... & 13 others	64/100
9th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 6 others	63/100
10th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	63/100
177th	Lysosomal Therapeutics 2011, Cambridge (United States), Series A	Small molecules to target Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies.	$58M	Sanofi Ventures, Roche & 11 others	37/100